Novel roles of c-met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression

Journal of Biological Chemistry

Volumn 290, Issue 13, 2015, Pages 8110-8120

  Balan, Murugabaskar ^a,b   Mier Y Teran, Eduardo ^a   Waaga Gasser, Ana Maria ^d   Gasser, Martin ^d   Choueiri, Toni K ^b,c   Freeman, Gordon ^b,c   Pal, Soumitro ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CYTOLOGY;

APOPTOTIC; CELL SURVIVAL; IMMUNE CELLS; OVER-EXPRESSION; RENAL CANCERS; THERAPEUTIC TARGETS; TYROSINE-KINASE RECEPTORS;

CELLS;

HEME OXYGENASE 1; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN BCL 2; PROTEIN BCL XL; RAF PROTEIN; RAS PROTEIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; CD274 PROTEIN, HUMAN; HMOX1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL CANCER CELL LINE; SIGNAL TRANSDUCTION; SPLEEN CELL; TISSUE DISTRIBUTION; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; ENZYMOLOGY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN TRANSPORT; TUMOR CELL CULTURE; TUMOR ESCAPE;

ANIMALS; ANTIGENS, CD274; APOPTOSIS; CARCINOMA, RENAL CELL; CELL SURVIVAL; COCULTURE TECHNIQUES; GENE EXPRESSION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEME OXYGENASE-1; HUMANS; KIDNEY NEOPLASMS; MICE, INBRED BALB C; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-MET; RAS PROTEINS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR ESCAPE;

EID: 84925778807     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.612689     Document Type: Article

References (49)

1. Ponzetto, C., Bardelli, A., Zhen, Z., Maina, F., dalla Zonca, P., Giordano, S., Graziani, A., Panayotou, G., and Comoglio, P. M. (1994)Amultifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77, 261-271
2. Birchmeier, C., Birchmeier, W., Gherardi, E., and Vande Woude, G. F. (2003) Met, metastasis, motility and more. Nature Reviews. Molecular Cell Biology 4, 915-925
3. Gherardi, E., Birchmeier, W., Birchmeier, C., and Vande Woude, G. (2012) Targeting MET in cancer: rationale and progress. Nature Reviews. Cancer 12, 89-103
4. Natali, P. G., Prat, M., Nicotra, M. R., Bigotti, A., Olivero, M., Comoglio, P. M., and Di Renzo, M. F. (1996) Overexpression of the met/HGF receptor in renal cell carcinomas. Int. J. Cancer 69, 212-217
5. Miyata, Y., Kanetake, H., and Kanda, S. (2006) Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma. Clin. Cancer Res. 12, 4876-4881
6. Nakaigawa, N., Yao, M., Baba, M., Kato, S., Kishida, T., Hattori, K., Nagashima, Y., and Kubota, Y. (2006) Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. Cancer Res. 66, 3699-3705
7. Kuroda, N., Tamura, M., Shiotsu, T., Nakamura, S., Taguchi, T., Tominaga, A., Hes, O., Michal, M., Kawada, C., Shuin, T., and Lee, G. H. (2010) Chromosomal abnormalities of clear cell renal cell carcinoma: frequent gain of chromosome. Pathol. Int. 60, 9-13
8. Bellon, S. F., Kaplan-Lefko, P., Yang, Y., Zhang, Y., Moriguchi, J., Rex, K., Johnson, C. W., Rose, P. E., Long, A. M., O'Connor, A. B., Gu, Y., Coxon, A., Kim, T. S., Tasker, A., Burgess, T. L., and Dussault, I. (2008) c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J. Biol. Chem. 283, 2675-2683
9. Gao, C. F., and Vande Woude, G. F. (2005) HGF/SF-Met signaling in tumor progression. Cell Res. 15, 49-51
10. Maina, F., Panté, G., Helmbacher, F., Andres, R., Porthin, A., Davies, A. M., Ponzetto, C., and Klein, R. (2001) Coupling Met to specific pathways results in distinct developmental outcomes. Mol. Cell 7, 1293-1306
11. Gusenbauer, S., Vlaicu, P., and Ullrich, A. (2013)HGFinduces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene 32, 3846-3856
12. Gibney, G. T., Aziz, S. A., Camp, R. L., Conrad, P., Schwartz, B. E., Chen, C. R., Kelly, W. K., and Kluger, H. M. (2013) c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann. Oncol. 24, 343-349
13. Agarwal, A., and Nick, H. S. (2000) Renal response to tissue injury: lessons from heme oxygenase-1 GeneAblation and expression. J. Am. Soc. Nephrol. 11, 965-973
14. Was, H., Dulak, J., and Jozkowicz, A. (2010) Heme oxygenase-1 in tumor biology and therapy. Curr. Drug Targets 11, 1551-1570
15. Banerjee, P., Basu, A., Datta, D., Gasser, M., Waaga-Gasser, A. M., and Pal, S. (2011) The heme oxygenase-1 protein is overexpressed in human renal cancer cells following activation of the Ras-Raf-ERK pathway and mediates anti-apoptotic signal. J. Biol. Chem. 286, 33580-33590
16. Nath, K. A. (2006) Heme oxygenase-1: a provenance for cytoprotective pathways in the kidney and other tissues. Kidney Int. 70, 432-443
17. Kamimoto, M., Mizuno, S., Matsumoto, K., and Nakamura, T. (2009) Hepatocyte growth factor prevents multiple organ injuries in endotoxemic mice through a heme oxygenase-1-dependent mechanism. Biochem. Biophys. Res. Commun. 380, 333-337
18. Ryter, S. W., Alam, J., and Choi, A. M. (2006) Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol. Rev. 86, 583-650
19. Suzuki, H., Tashiro, S., Hira, S., Sun, J., Yamazaki, C., Zenke, Y., Ikeda-Saito, M., Yoshida, M., and Igarashi, K. (2004) Heme regulates gene expression by triggering Crm1-dependent nuclear export of Bach1. EMBO J. 23, 2544-2553
20. Kim, T. H., Hur, E. G., Kang, S. J., Kim, J. A., Thapa, D., Lee, Y. M., Ku, S. K., Jung, Y., and Kwak, M. K. (2011) NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. Cancer Res. 71, 2260-2275
21. Uzzo, R. G., Rayman, P., Kolenko, V., Clark, P. E., Bloom, T., Ward, A. M., Molto, L., Tannenbaum, C., Worford, L. J., Bukowski, R., Tubbs, R., Hsi, E. D., Bander, N. H., Novick, A. C., and Finke, J. H. (1999) Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin. Cancer Res. 5, 1219-1229
22. Chen, L., and Flies, D. B. (2013) Molecular mechanisms of T cell costimulation and co-inhibition. Nature reviews. Immunology 13, 227-242
23. Keir, M. E., Butte, M. J., Freeman, G. J., and Sharpe, A. H. (2008) PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704
24. Blank, C., Gajewski, T. F., and Mackensen, A. (2005) Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol., Immunotherapy 54, 307-314
25. Pilon-Thomas, S., Mackay, A., Vohra, N., and Mulé, J. J. (2010) Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J. Immunol. 184, 3442-3449
26. Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., Tamada, K., and Chen, L. (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65, 1089-1096
27. Thompson, R. H., Dong, H., Lohse, C. M., Leibovich, B. C., Blute, M. L., Cheville, J. C., and Kwon, E. D. (2007) PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res. 13, 1757-1761
28. Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., Zincke, H., Blute, M. L., Strome, S. E., Leibovich, B. C., and Kwon, E. D. (2004) Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl. Acad. Sci. U. S. A. 101, 17174-17179
29. Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S., Frank, I., Parker, A. S., Zincke, H., Blute, M. L., Sebo, T. J., Cheville, J. C., and Kwon, E. D. (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with longterm follow-up. Cancer Res. 66, 3381-3385
30. Yakes, F. M., Chen, J., Tan, J., Yamaguchi, K., Shi, Y., Yu, P., Qian, F., Chu, F., Bentzien, F., Cancilla, B., Orf, J., You, A., Laird, A. D., Engst, S., Lee, L., Lesch, J., Chou, Y. C., and Joly, A. H. (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Therap. 10, 2298-2308
31. Khosravi-Far, R., White, M. A., Westwick, J. K., Solski, P. A., Chrzanowska-Wodnicka, M., Van Aelst, L., Wigler, M. H., and Der, C. J. (1996) Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol. Cell. Biol. 16, 3923-3933
32. Datta, D., Contreras, A. G., Basu, A., Dormond, O., Flynn, E., Briscoe, D. M., and Pal, S. (2009) Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res. 69, 8902-8909
33. Yeung, K., Seitz, T., Li, S., Janosch, P., McFerran, B., Kaiser, C., Fee, F., Katsanakis, K. D., Rose, D. W., Mischak, H., Sedivy, J. M., and Kolch, W. (1999) Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401, 173-177
34. Balan, M., and Pal, S. (2014) A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocation. J. Biol. Chem. 289, 3126-3137
35. Chora, A. A., Fontoura, P., Cunha, A., Pais, T. F., Cardoso, S., Ho, P. P., Lee, L. Y., Sobel, R. A., Steinman, L., and Soares, M. P. (2007) Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J. Clin. Investig. 117, 438-447
36. Tzima, S., Victoratos, P., Kranidioti, K., Alexiou, M., and Kollias, G. (2009) Myeloid heme oxygenase-1 regulates innate immunity and autoimmunity by modulating IFN-β production. J. Exp. Med. 206, 1167-1179
37. Datta, D., Flaxenburg, J. A., Laxmanan, S., Geehan, C., Grimm, M., Waaga-Gasser, A. M., Briscoe, D. M., and Pal, S. (2006) Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res. 66, 9509-9518
38. Fujita, J., Kraus, M. H., Onoue, H., Srivastava, S. K., Ebi, Y., Kitamura, Y., and Rhim, J. S. (1988) Activated H-ras oncogenes in human kidney tumors. Cancer Res. 48, 5251-5255
39. Margolis, B., and Skolnik, E. Y. (1994) Activation of Ras by receptor tyrosine kinases. J. Am. Soc. Nephrol. 5, 1288-1299
40. Tanimoto, S., Fukumori, T., El-Moula, G., Shiirevnyamba, A., Kinouchi, S., Koizumi, T., Nakanishi, R., Yamamoto, Y., Taue, R., Yamaguchi, K., Nakatsuji, H., Kishimoto, T., Izaki, H., Oka, N., Takahashi, M., and Kanayama, H. O. (2008) Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor. J. Med. Investig. 55, 106-111
41. Ke, B., Shen, X. D., Ji, H., Kamo, N., Gao, F., Freitas, M. C., Busuttil, R. W., and Kupiec-Weglinski, J. W. (2012) HO-1-STAT3 axis in mouse liver ischemia/reperfusion injury: regulation of TLR4 innate responses through PI3K/PTEN signaling. J. Hepatol. 56, 359-366
42. Mizuno, S., and Nakamura, T. (2012) Improvement of sepsis by hepatocyte growth factor, an anti-inflammatory regulator: emerging insights and therapeutic potential. Gastroenterol. Res. Pract. 2012, 909350
43. Singhal, E., Kumar, P., and Sen, P. (2011) A novel role for Bruton's tyrosine kinase in hepatocyte growth factor-mediated immunoregulation of dendritic cells. J. Biol. Chem. 286, 32054-32063
44. Skibinski, G. (2003) The role of hepatocyte growth factor/c-met interactions in the immune system. Archivum immunologiae et therapiae experimentalis 51, 277-282
45. Benkhoucha, M., Santiago-Raber, M. L., Schneiter, G., Chofflon, M., Funakoshi, H., Nakamura, T., and Lalive, P. H. (2010) Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 107, 6424-6429
46. Baek, J. H., Birchmeier, C., Zenke, M., and Hieronymus, T. (2012) The HGF receptor/Met tyrosine kinase is a key regulator of dendritic cell migration in skin immunity. J. Immunol. 189, 1699-1707
47. Rayman, P., Wesa, A. K., Richmond, A. L., Das, T., Biswas, K., Raval, G., Storkus, W. J., Tannenbaum, C., Novick, A., Bukowski, R., and Finke, J. (2004) Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin. Cancer Res. 10, 6360S-6366S
48. Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., and Nakajima, Y. (2007) Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 13, 2151-2157
49. Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., David, O., Burow, M., Gordon, A., Dhurandhar, N., Myers, L., Berggren, R., Hemminki, A., Alvarez, R. D., Emilie, D., Curiel, D. T., Chen, L., and Zou, W. (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Medicine 9, 562-567